Anebulo Pharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -9.07 | -100% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
18.96 | 4.82 | 293.39% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-8.6 | -22.15 | -61.19% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
-8.55 | 68.78 | -112.44% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.98 | -100% | 0 | 0% |
| ROE |
|
-113.8 | 9.61 | -1284.02% |
|
|
| ROA |
|
-104.19 | 0.3443 | -30365.88% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-217.93 | 15.35 | -1519.73% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | -3.68 | -100% | -0.2903 | -100% |
| Nеt Debt/Ebitda |
|
0.3844 | -3.44 | -111.18% |
|
|
| Debt/Ratio |
|
0 | 0.1985 | -100% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
0 | 10.32 | -100% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5442 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2237 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9889 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4952 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5442 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -56.89 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
123.62 | -54.68 | -326.08% | ||
| Growth impulse Net Income in 5 years |
|
-72.93 | -58.33 | 25.03% | ||
| Growth impulse FCF in 5 years |
|
65.12 | -49.48 | -231.61% | ||
| Growth impulse EPS in 5 years |
|
-75.49 | -32.41 | 132.92% |
IP Score
3.2/10
